摘要
目的 探讨抑癌基因E cadherin(E cad)、p16蛋白及ER在前列腺病变组织中的表达及临床意义。 方法 应用免疫组化技术检测 13例良性前列腺增生 ,10例高级别前列腺上皮内瘤变和 2 0例前列腺癌组织中E cad、p16及ER的表达。结果前列腺癌中 ,E cad表达明显减低 ,p16蛋白表达增加 ;发生转移的癌中E cad蛋白表达显著减弱 ;p16蛋白的表达在HGPIN组与低Gleason评分前列腺癌组间差异存在显著性。ER在所有前列腺病变的上皮中无表达。结论 E cad和p16蛋白的免疫组化检测 ,结合血清PSA水平可作为前列腺癌诊断的辅助手段 ;p16蛋白的检测有助于HGPIN与高分化癌的鉴别 ;E cad蛋白的表达可作为判断预后的指标。
Purpose To investigate the expression and significance of E-cadherin (E-cad), p16 and ER in prostatic lesions. Methods The expression of E-cad, p16 and ER was evaluated by immunohistochemistry in 13 cases of benign prostate hyperplasia, 10 cases of high grade PIN and 20 cases of prostate carcinoma. Results In high-grade prostatic carcinoma, tumor cells showed low expression of E-cad and overexpression of p16. ER immunostaining was not detected in the epithalium of all prostatic lesions and occasionally detected in basal cells and stromal cells. Conclusions Overexpression of p16 is helpful to differentiate HGPIN from low grade prostate carcinoma, and E-cad may be functioned as useful markers for predicting the clinical prognosis.
出处
《临床与实验病理学杂志》
CAS
CSCD
2004年第6期698-701,共4页
Chinese Journal of Clinical and Experimental Pathology
